This article was originally published in Start Up
CardioPhotonics' HeartLight monitors fluid volumes in real time and is normalized to patients during surgery. The company believes that the ability to accurately assess the patient’s condition and consequently avoid the over- or underadministration of fluids will reduce post-surgical complications that can prolong hospital stay and increase health care costs.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. "As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors," features profiles of Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharmaceuticals. Plus these Start-Ups Across Health Care: CardioPhotonics, Eureka Genomics, Invuity and OrthoSensor.
Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.